Patents by Inventor John Trowsdale

John Trowsdale has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-Siglec-15 antibodies and uses thereof
    Patent number: 9994636
    Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: June 12, 2018
    Assignees: MedImmune Limited, Cambridge Enterprise Limited
    Inventors: John Elvin, Catherine Huntington, John Trowsdale, Alexander Barrow, Huan Cao
  • ANTI-SIGLEC-15 ANTIBODIES AND USES THEREOF
    Publication number: 20170029503
    Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
    Type: Application
    Filed: August 9, 2016
    Publication date: February 2, 2017
    Inventors: John Elvin, Catherine Huntington, John Trowsdale, Alexander Barrow, Huan Cao
  • Anti-Siglec-15 antibodies and uses thereof
    Patent number: 9447192
    Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
    Type: Grant
    Filed: September 6, 2012
    Date of Patent: September 20, 2016
    Assignees: MEDIMMUNE LIMITED, CAMBRIDGE ENTERPRISE LIMITED
    Inventors: John Elvin, Catherine Huntington, John Trowsdale, Alexander Barrow, Huan Cao
  • ANTI-SIGLEC-15 ANTIBODIES AND USES THEREOF
    Publication number: 20150037356
    Abstract: This disclosure relates to anti-Siglec-15 antibodies and uses thereof, in particular in the treatment of leukaemia, such as acute myeloid leukaemia.
    Type: Application
    Filed: September 6, 2012
    Publication date: February 5, 2015
    Applicants: CAMBRIDGE ENTERPRISE LIMITED, MEDIMMUNE LIMITED
    Inventors: John Elvin, Catherine Huntington, John Trowsdale, Alexander Barrow, Huan Cao
  • Modulation of the activity and differentiation of cells expressing the osteoclast-associated receptor
    Patent number: 8642728
    Abstract: This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OS-CAR expressing cells.
    Type: Grant
    Filed: October 6, 2009
    Date of Patent: February 4, 2014
    Assignee: Cambridge Enterprise Ltd.
    Inventors: John Trowsdale, Alexander Barrow, Richard Farndale
  • Modulation of the Activity and Differentiation of Cells Expressing the Osteoclast-Associated Receptor
    Publication number: 20130280273
    Abstract: This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OSCAR expressing cells.
    Type: Application
    Filed: December 17, 2012
    Publication date: October 24, 2013
    Inventors: John Trowsdale, Alexander Barrow, Richard Farndale
  • MODULATION OF THE ACTIVITY AND DIFFERENTIATION OF CELLS EXPRESSING THE OSTEOCLAST-ASSOCIATED RECEPTOR
    Publication number: 20120028903
    Abstract: This invention relates to the finding that collagen peptides bind to the osteoclast-associated receptor (OSCAR) and stimulate the activation and/or differentiation of OSCAR expressing cells, such as osteoclasts and osteoclast precursor cells. Collagen peptides are described which may be useful in the modulation of the differentiation and/or activation of OSCAR expressing cells, for example in the treatment of bone defects and disorders characterized by altered differentiation and/or activation of OS-CAR expressing cells.
    Type: Application
    Filed: October 6, 2009
    Publication date: February 2, 2012
    Applicant: Cambridge Enterprise Limited
    Inventors: John Trowsdale, Alexander Barrow, Richard Farndale
  • Proteins Ligands For Nkg2d And Ul16 Receptors And Uses Thereof
    Publication number: 20080038248
    Abstract: A novel member of the RAET1/ULBP family of proteins (RAET1G) is identified and characterised and shown to bind the UL16 and NKG2D receptors with high affinity. RAET1G exhibits restricted expression in normal tissues but exhibits high levels of expression in tumours and may be differentially spliced in cancer cells to produce a soluble protein. RAET1G is also up-regulated in inflammatory diseases such as coeliac disease. RAET1G may be used as a novel marker for disease conditions including cancer conditions and inflammatory diseases.
    Type: Application
    Filed: February 17, 2005
    Publication date: February 14, 2008
    Inventors: John Trowsdale, Robert Eagle, Louise Bacon